Literature DB >> 15538186

Neuregulin genotype and medication response in Finnish patients with schizophrenia.

Olli Kampman1, Sami Anttila, Ari Illi, Marika Saarela, Riikka Rontu, Kari M Mattila, Esa Leinonen, Terho Lehtimäki.   

Abstract

Neuregulin 1 is involved both in neurodevelopment and neurotransmitter mechanisms in the brain. There is evidence of an association between neuregulin 1 genotype and schizophrenia. We compared neuregulin 1 genotypes in patients with schizophrenia (n=94) and control subjects (n=395) of Finnish origin by using one SNP (SNP8NRG221533) as a genetic marker. We also analyzed NRG1 genotype with regard to age at onset and between responders and non-responders to conventional antipsychotics. The NRG1 genotype or allele frequencies showed similar distributions between patient and control groups. Age at onset was not associated with NRG1 genotype. The TT genotype was overrepresented in the non-responders group compared with the responders (p=0.013). Further studies are needed to ascertain the significance of neuregulin genotype in medication response to schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538186     DOI: 10.1097/00001756-200411150-00017

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  15 in total

Review 1.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

Review 2.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 3.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

4.  Lack of associations of neuregulin 1 variations with schizophrenia and smooth pursuit eye movement abnormality in a Korean population.

Authors:  Jeong-Hyun Kim; Byung-Lae Park; Charisse Flerida A Pasaje; Joon Seol Bae; Chul Soo Park; Boseok Cha; Bong-Jo Kim; Migyung Lee; Woo Hyuk Choi; Tae-Min Shin; Ihn-Geun Choi; Jaeuk Hwang; Insong Koh; Sung-Il Woo; Hyoung Doo Shin
Journal:  J Mol Neurosci       Date:  2011-08-20       Impact factor: 3.444

Review 5.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

Review 6.  Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies.

Authors:  Andrea Schmitt; Eleni Parlapani; Oliver Gruber; Thomas Wobrock; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

7.  Neuregulin 1 genotype and schizophrenia.

Authors:  Marcus R Munafò; Angela S Attwood; Jonathan Flint
Journal:  Schizophr Bull       Date:  2007-11-20       Impact factor: 9.306

8.  Family-based association study of Neuregulin 1 with psychotic bipolar disorder.

Authors:  Fernando S Goes; Virginia L Willour; Peter P Zandi; Pamela L Belmonte; Dean F MacKinnon; Francis M Mondimore; Barbara Schweizer; Elliot S Gershon; Francis J McMahon; James B Potash
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-07-05       Impact factor: 3.568

9.  Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia.

Authors:  Kari Hänninen; Heikki Katila; Marika Saarela; Riikka Rontu; Kari M Mattila; Meng Fan; Mikko Hurme; Terho Lehtimäki
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-09-27       Impact factor: 5.270

10.  Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia.

Authors:  Andrea Schmitt; Jiri Koschel; Mathias Zink; Manfred Bauer; Clemens Sommer; Josef Frank; Jens Treutlein; Thomas Schulze; Thomas Schneider-Axmann; Eleni Parlapani; Marcella Rietschel; Peter Falkai; Fritz A Henn
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-05-12       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.